• XORTX outlined plans to file a Health Canada clinical trial application for XRx-026, extending its international regulatory strategy for gout.
• The planned two-part XRX-OXY-102 study will evaluate XORLO, its oxypurinol formulation, to support a future US FDA new drug application.
• Part one in Canada is intended to speed delivery of key clinical data for the program.
• Positive clinical results for the formulation were already reported; the upcoming study will further characterize the commercial tablet form.
• XORTX flagged increased partner interest across jurisdictions, with no agreements signed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XORTX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610081600PRIMZONEFULLFEED9841975) on October 08, 2026, and is solely responsible for the information contained therein.